Research Topics
Genomes and Genes | Barry S TaylorSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomasBarry S Taylor
Memorial Sloan Kettering Cancer Center, NY 10065, USA
Cancer Discov 1:587-97. 2011..Pharmacologic inhibition of DNA methylation promoted apoptosis and differentiated DLPS cells in vitro and inhibited tumor growth in vivo, providing a rationale for investigating methylation inhibitors in this disease...
Clinical cancer genomics: how soon is now?Barry S Taylor
Program in Computational Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Pathol 223:318-26. 2011..Whether these will impact routine clinical practice and the treatment of disease is no longer debatable, but how precisely this will happen is a source of ongoing speculation and development...- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerEric W Joseph
Weill Cornell Graduate School of Medical Sciences, New York, NY 10065, USA
Proc Natl Acad Sci U S A 107:14903-8. 2010..This selectivity may lead to a broader therapeutic index and help explain the greater antitumor activity observed with this drug than with MEK inhibitors... - Genomic and biological characterization of exon 4 KRAS mutations in human cancerManickam Janakiraman
Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Cancer Res 70:5901-11. 2010..These results also provide a rationale for broader KRAS testing beyond the most common hotspot alleles in exons 2 and 3... - Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instabilityAimee M Crago
Sarcoma Disease Management Program, Department of Surgery, Bioinformatics Core, Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 18:1334-40. 2012..This study sought to identify copy number alterations (CNA) associated with dedifferentiation of WDLS, with DDLS morphology, and with patient outcomes... - Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignanciesSelvaraju Veeriah
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Nat Genet 42:77-82. 2010..These data strongly point to PARK2 as a tumor suppressor on 6q25.2-q27. Thus, PARK2, a gene that causes neuronal dysfunction when mutated in the germline, may instead contribute to oncogenesis when altered in non-neuronal somatic cells... - Integrative genomic profiling of human prostate cancerBarry S Taylor
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Cancer Cell 18:11-22. 2010..The genomic and clinical outcome data from these patients are now made available as a public resource... - Genome sequencing identifies a basis for everolimus sensitivityGopa Iyer
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Science 338:221. 2012.... - MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitorsNicola J Clegg
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
PLoS ONE 6:e17449. 2011..Since increased MYC expression is an early feature of many human prostate cancers, these data have implications for treatment of human prostate cancers with PI3K-pathway alterations using mTOR inhibitors... - ZIC1 overexpression is oncogenic in liposarcomaElliott Brill
Department of Surgery, Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Cancer Res 70:6891-901. 2010..Our results show that ZIC1 expression is essential for liposarcomagenesis and that targeting ZIC1 or its downstream targets might lead to novel therapy for liposarcoma... - Advances in sarcoma genomics and new therapeutic targetsBarry S Taylor
Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Nat Rev Cancer 11:541-57. 2011.... - Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcomaStacy Ugras
Department of Surgery, Sarcoma Biology Laboratory, Sarcoma Disease Management Program, The Rockefeller University, New York, New York, USA
Cancer Res 71:5659-69. 2011..Taken together, our findings suggest that miR-143 re-expression vectors or selective agents directed at miR-143 or its targets may have therapeutic value in dedifferentiated liposarcoma... - Genomic complexity and AKT dependence in serous ovarian cancerAphrothiti J Hanrahan
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10471, USA
Cancer Discov 2:56-67. 2012.... - Automated network analysis identifies core pathways in glioblastomaEthan Cerami
Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
PLoS ONE 5:e8918. 2010..A central challenge in large-scale genome projects, such as the TCGA GBM project, is the ability to distinguish cancer-causing "driver" mutations from passively selected "passenger" mutations... - Functional copy-number alterations in cancerBarry S Taylor
Computational Biology Center, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
PLoS ONE 3:e3179. 2008..Taken together, we present a statistically robust methodology applicable to high-resolution genomic data to assess the extent and function of copy-number alterations in cancer... - The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesotheliomaMatthew Bott
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Nat Genet 43:668-72. 2011..These findings implicate transcriptional deregulation in the pathogenesis of MPM... - Genetic predictors of MEK dependence in non-small cell lung cancerChristine A Pratilas
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Cancer Res 68:9375-83. 2008.... - Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancersLuc G T Morris
Human Oncology and Pathogenesis Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Proc Natl Acad Sci U S A 108:19024-9. 2011..These findings have important implications for our understanding of head and neck cancer tumorigenesis and for the use of targeted agents for this malignancy... - (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathwayChristine A Pratilas
Department of Pediatrics, Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Proc Natl Acad Sci U S A 106:4519-24. 2009..Physiologic feedback inhibition of RAF/MEK signaling down-regulates ERK output in RTK cells; evasion of this feedback in mutant BRAF cells is associated with increased transcriptional output and MEK/ERK-dependent transformation...